120 related articles for article (PubMed ID: 33676785)
1. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center.
Rojas-Pintor KP; Arizmendi-Villarreal MA; Aparicio-Salas JE; Moreno-Peña DP; Hernández-Barajas D; Cordero-Pérez P; Muñoz-Espinosa LE
Rev Gastroenterol Mex (Engl Ed); 2021 Mar; ():. PubMed ID: 33676785
[TBL] [Abstract][Full Text] [Related]
2. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center.
Rojas-Pintor KP; Arizmendi-Villarreal MA; Aparicio-Salas JE; Moreno-Peña DP; Hernández-Barajas D; Cordero-Pérez P; Muñoz-Espinosa LE
Rev Gastroenterol Mex (Engl Ed); 2021; 86(4):370-377. PubMed ID: 34384724
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
4. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
5. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
6. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
7. AFP score and metroticket 2.0 perform similarly and could be used in a "within-ALL" clinical decision tool.
Piñero F; Costentin C; Degroote H; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas A; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Dibenedetto F; Duque SH; Salame E; Cillo U; Marciano S; Vanlemmens C; Fagiuoli S; Carrilho F; Cherqui D; Burra P; Van Vlierberghe H; Lai Q; Silva M; Rubinstein F; Duvoux C; ; ; ; ;
JHEP Rep; 2023 Feb; 5(2):100644. PubMed ID: 36691474
[TBL] [Abstract][Full Text] [Related]
8. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital.
Togashi J; Akamastu N; Kokudo N
Hepatobiliary Surg Nutr; 2016 Oct; 5(5):399-407. PubMed ID: 27826554
[TBL] [Abstract][Full Text] [Related]
9. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.
Costentin C; Piñero F; Degroote H; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Podestá LG; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Dibenedetto F; Duque SH; Salame E; Cillo U; Marciano S; Vanlemmens C; Fagiuoli S; Burra P; Van Vlierberghe H; Cherqui D; Lai Q; Silva M; Rubinstein F; Duvoux C;
JHEP Rep; 2022 May; 4(5):100445. PubMed ID: 35360522
[TBL] [Abstract][Full Text] [Related]
10. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
11. Hypoalbuminemia Is a Hepatocellular Carcinoma Independent Risk Factor for Tumor Progression in Low-Risk Bridge to Transplant Candidates.
Núñez KG; Sandow T; Patel J; Hibino M; Fort D; Cohen AJ; Thevenot P
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406456
[TBL] [Abstract][Full Text] [Related]
12. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria.
Magro B; Pinelli D; De Giorgio M; Lucà MG; Ghirardi A; Carrobio A; Baronio G; Del Prete L; Nounamo F; Gianatti A; Colledan M; Fagiuoli S
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885087
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
14. Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant.
Brandão ABM; Rodriguez S; Fleck AM; Marroni CA; Wagner MB; Hörbe A; Fernandes MV; Cerski CT; Coral GP
World J Clin Oncol; 2022 Aug; 13(8):688-701. PubMed ID: 36160465
[TBL] [Abstract][Full Text] [Related]
15. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation in patients with incidental hepatocellular carcinoma/cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-center experience.
Elshamy M; Presser N; Hammad AY; Firl DJ; Coppa C; Fung J; Aucejo FN
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):264-270. PubMed ID: 28603094
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels.
She WH; Chan ACY; Cheung TT; Lo CM; Chok KSH
World J Hepatol; 2018 Feb; 10(2):308-318. PubMed ID: 29527266
[TBL] [Abstract][Full Text] [Related]
18. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
19. High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation.
He JJ; Shang L; Yu QW; Jiao N; Qiu S; Zhu WX; Wu DF; Tian YE; Zhang Q
World J Gastrointest Oncol; 2021 Jul; 13(7):716-731. PubMed ID: 34322200
[TBL] [Abstract][Full Text] [Related]
20. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
